Last reviewed · How we verify
SAXAGLIPTIN
Saxagliptin is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | SAXAGLIPTIN |
|---|---|
| Drug class | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Urinary tract infection
- Genital mycotic infections
- Impairment of renal function
- Upper respiratory tract infection
- Dyslipidemia
Serious adverse events
- Severe hypoglycemia
- Hypoglycemia
- Volume depletion
- Pyelonephritis
Key clinical trials
- Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Comparison of Type 2 Diabetes Pharmacotherapy Regimens
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
- Robson Ten-Group Classification Study of Cesarean Section Rates in Assiut Hospitals
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) (NA)
- SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAXAGLIPTIN CI brief — competitive landscape report
- SAXAGLIPTIN updates RSS · CI watch RSS